{"id":47876,"date":"2022-09-01T07:01:38","date_gmt":"2022-09-01T05:01:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/"},"modified":"2022-09-01T07:01:38","modified_gmt":"2022-09-01T05:01:38","slug":"cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/","title":{"rendered":"Cerveau Technologies Inc. and Alnylam\u00ae Pharmaceuticals Sign Agreement to Provide Novel\u00a0Tau\u00a0Imaging Biomarker for Disease Modifier Research"},"content":{"rendered":"<div>\n<p>BOSTON&#8211;(BUSINESS WIRE)&#8211;Cerveau Technologies, Inc. today announced a research collaboration agreement with Alnylam<sup>\u00ae<\/sup> Pharmaceuticals (Alnylam), which will enable Alnylam to use Cerveau\u2019s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer\u2019s disease.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220831005772\/en\/1558558\/4\/cerveau_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220831005772\/en\/1558558\/21\/cerveau_logo.jpg\"><\/a><\/p>\n<p>\nThe collaboration is focused on using [F-18]MK-6240 as a biomarker in Alnylam\u2019s neurodegenerative disease drug research and development. The companies will apply [F-18]MK-6240 imaging to evaluate Alnylam\u2019s investigational therapeutics for potential treatment of neurodegenerative diseases in humans, with a focus on Mild Cognitive Impairment and pre-symptomatic Alzheimer\u2019s Disease.\n<\/p>\n<p>\n\u201cCerveau is focused on enabling acceleration of technologies that have the potential to advance the fight against debilitating neurodegenerative diseases,\u201d said Rick Hiatt, Chief Executive Officer, Cerveau Technologies, Inc. \u201cWe are excited to add Alnylam to our growing network of pharmaceutical partners and global validated production sites. Our goal is to expand the availability of this novel investigational imaging agent to the broader scientific community.\u201d\n<\/p>\n<p>\n<b>About Cerveau Technologies, Inc.<\/b>\n<\/p>\n<p>\nCerveau\u2019s vision is globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer\u2019s disease.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nCerveau Technologies, Inc.<br \/>\n<br \/>Rick Hiatt, 617-906-2715<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;o&#58;&#x52;F&#x68;&#x69;&#97;&#x74;t&#64;&#x63;e&#114;&#x76;e&#x61;&#x75;&#116;&#x65;&#x63;&#104;&#x6e;o&#108;&#x6f;g&#105;&#x65;s&#x2e;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">R&#70;&#104;&#x69;&#x61;&#x74;t&#64;&#99;&#101;&#x72;&#x76;&#x65;a&#117;&#116;&#101;&#x63;&#x68;&#x6e;o&#108;&#111;&#x67;&#x69;&#x65;s&#46;&#99;&#111;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON&#8211;(BUSINESS WIRE)&#8211;Cerveau Technologies, Inc. today announced a research collaboration agreement with Alnylam\u00ae Pharmaceuticals (Alnylam), which will enable Alnylam to use Cerveau\u2019s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47876","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cerveau Technologies Inc. and Alnylam\u00ae Pharmaceuticals Sign Agreement to Provide Novel\u00a0Tau\u00a0Imaging Biomarker for Disease Modifier Research - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cerveau Technologies Inc. and Alnylam\u00ae Pharmaceuticals Sign Agreement to Provide Novel\u00a0Tau\u00a0Imaging Biomarker for Disease Modifier Research - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON&#8211;(BUSINESS WIRE)&#8211;Cerveau Technologies, Inc. today announced a research collaboration agreement with Alnylam\u00ae Pharmaceuticals (Alnylam), which will enable Alnylam to use Cerveau\u2019s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-01T05:01:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220831005772\/en\/1558558\/21\/cerveau_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cerveau Technologies Inc. and Alnylam\u00ae Pharmaceuticals Sign Agreement to Provide Novel\u00a0Tau\u00a0Imaging Biomarker for Disease Modifier Research\",\"datePublished\":\"2022-09-01T05:01:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/\"},\"wordCount\":238,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220831005772\\\/en\\\/1558558\\\/21\\\/cerveau_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/\",\"name\":\"Cerveau Technologies Inc. and Alnylam\u00ae Pharmaceuticals Sign Agreement to Provide Novel\u00a0Tau\u00a0Imaging Biomarker for Disease Modifier Research - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220831005772\\\/en\\\/1558558\\\/21\\\/cerveau_logo.jpg\",\"datePublished\":\"2022-09-01T05:01:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220831005772\\\/en\\\/1558558\\\/21\\\/cerveau_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220831005772\\\/en\\\/1558558\\\/21\\\/cerveau_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cerveau Technologies Inc. and Alnylam\u00ae Pharmaceuticals Sign Agreement to Provide Novel\u00a0Tau\u00a0Imaging Biomarker for Disease Modifier Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cerveau Technologies Inc. and Alnylam\u00ae Pharmaceuticals Sign Agreement to Provide Novel\u00a0Tau\u00a0Imaging Biomarker for Disease Modifier Research - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/","og_locale":"en_US","og_type":"article","og_title":"Cerveau Technologies Inc. and Alnylam\u00ae Pharmaceuticals Sign Agreement to Provide Novel\u00a0Tau\u00a0Imaging Biomarker for Disease Modifier Research - Pharma Trend","og_description":"BOSTON&#8211;(BUSINESS WIRE)&#8211;Cerveau Technologies, Inc. today announced a research collaboration agreement with Alnylam\u00ae Pharmaceuticals (Alnylam), which will enable Alnylam to use Cerveau\u2019s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-01T05:01:38+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220831005772\/en\/1558558\/21\/cerveau_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cerveau Technologies Inc. and Alnylam\u00ae Pharmaceuticals Sign Agreement to Provide Novel\u00a0Tau\u00a0Imaging Biomarker for Disease Modifier Research","datePublished":"2022-09-01T05:01:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/"},"wordCount":238,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220831005772\/en\/1558558\/21\/cerveau_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/","url":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/","name":"Cerveau Technologies Inc. and Alnylam\u00ae Pharmaceuticals Sign Agreement to Provide Novel\u00a0Tau\u00a0Imaging Biomarker for Disease Modifier Research - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220831005772\/en\/1558558\/21\/cerveau_logo.jpg","datePublished":"2022-09-01T05:01:38+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220831005772\/en\/1558558\/21\/cerveau_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220831005772\/en\/1558558\/21\/cerveau_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-alnylam-pharmaceuticals-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cerveau Technologies Inc. and Alnylam\u00ae Pharmaceuticals Sign Agreement to Provide Novel\u00a0Tau\u00a0Imaging Biomarker for Disease Modifier Research"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47876"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47876\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47876"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47876"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}